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Khalil J. Diab,1 Zhangsheng Yu,2 Karen L. Wood,3 James A. Shmalo,4
Francis D. Sheski,1 Mark O. Farber,1 David S. Wilkes,1 Robert P. Nelson Jr.5Nonmyeloablative conditioning before allogeneic hematopoietic cell transplant (HCT) is an alternative to
conventional conditioning in older patients and those with comorbidities. It is not known whether the
decreased tissue injury associated with nonmyeloablative conditioning lowers the risk of pulmonary compli-
cations. The medical records of patients who underwent transplantation were reviewed and all pulmonary
complications documented. Sixty-two consecutive patients with hematologic malignancies who underwent
minimally intensive HCT (subjects) were compared to 48 consecutive patients who received conventional
myeloablative allogeneic peripheral blood HCT (controls) over the same period at Indiana University Hos-
pital. Pulmonary complications were categorized according to the type of complication and the time of onset
after transplantation. Median follow-up times were similar between groups (P 5 .70). The study population
(minimal intensity recipients) was older (P\ .01), and the incidence of chronic graft-versus-host disease
(cGVHD) was higher in subjects than controls (P 5 .02). Sixty-nine percent of subjects and 73% of controls
developed pulmonary complications (P 5 .70). There was a trend in the minimally conditioned patients to-
wards a lower incidence of pulmonary complications in older patients in the early posttransplantation period
and a higher incidence of infectious pneumonias and bronchiolitis obliterans syndrome at later time points.
The frequency of pulmonary complications seems to be similar after minimally intensive or myeloablative
conditioning and allotransplantation. There was no difference in overall mortality or pulmonary-related
mortality between the 2 groups.
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complications. These included a preponderance of
interstitial pneumonitis secondary to cytomegalovirus
(CMV) [1].Multiple subsequent studies document a va-
riety of lung pathology after bonemarrow transplant in
patients of all ages [2-7]. These reports demonstrate an
association among pulmonary complications, chronic
graft-versus-host disease (cGVHD), and CMV [8-10].
cGVHD is associated with the development of bron-
chiolitis obliterans syndrome (BOS), cryptogenic orga-
nizing pneumonia, and/or infectious pneumonias
[8,11,12]. Idiopathic pneumonia syndrome, a pulmo-
nary complication that is frequently fatal, is associated
with high dosages of chemotherapy and/or radiation
therapy used in conventional, myeloablative condition-
ing [13-15]. Infectious and noninfectious pulmonary
complications are the most common causes of mortal-
ity and critical illness after hematopoietic cell trans-
plant (HCT) [7,16-19].
Reduced intensity conditioning includes ‘‘reduced
toxicity’’ myeloablative and ‘‘minimal intensity’’ non-
myeloablative regimens [20-25]. These transplantation1827
1828 Biol Blood Marrow Transplant 18:1827-1834, 2012K. J. Diab et al.methods are characterized by high engraftment rates,
comparatively low transplant-related mortality, and
variable disease responses. Minimally intensive condi-
tioning does not eradicate host hematopoiesis and per-
mits prompt (\4 weeks) autologous hematological
recovery after transplantation. It is characterized by
mixed chimerism upon initial engraftment and circum-
vents mucositis and sinusoidal obstructive liver disease
[26-30]. It also permits transplantation of older patients
and/or those with comorbid illnesses, including those
with preexisting pulmonary conditions who may not
otherwise be considered allotransplant candidates.
We hypothesized that minimally intensive condition-
ing would be associated with lower incidence of pul-
monary complications, particularly those that occur
in the early posttransplantation period, including
diffuse alveolar hemorrhage and idiopathic pneumonia
syndrome [31,32]. We describe herein the incidence
and character of pulmonary complications after mini-
mally intensive conditioning and compare with that
of a control group of patients who underwent conven-
tional transplantations.MATERIALS AND METHODS
The study population included 62 consecutive
patients (subjects) who underwent minimally intensive
conditioning and 48 consecutive patients (controls)
who underwent conventional myeloablative condi-
tioning at Indiana University. The patients in both
groups underwent transplantation between 2000 and
2006. A research protocol for nonmyeloablative allo-
geneic transplantation (NMAT) at our institution
was developed in May 2000, utilizing the nonmyeloa-
blative conditioning regimen of Khouri et al. [22] and
Childs et al. [33]. The objectives, inclusion, and exclu-
sion criteria of this protocol have been described pre-
viously [29]. Consecutive patients who underwent
conventional myeloablative conditioning for the treat-
ment of hematologic malignancies over the same time
period were selected as controls.
Conditioning Regimens
Minimally intensive conditioning for both related
and unrelated recipients included cyclophosphamide,
120 mg/kg, and fludarabine, 125 mg/m2. GVHD pro-
phylaxis consisted of cyclosporineA, 3mg/kg/day, initi-
ated on day21 and continued until the patient tolerated
oral administration. Thirty-three subjects also received
mycophenolate mofetil at a dose of 1000mg twice a day
i.v./prescribed orally beginning on day 11.
Conventional conditioning for both related and
unrelated recipients included the following regimens:
(1) cyclophosphamide 120 mg/kg and busulfan 12.8
to 16 mg/kg, or (2) cyclophosphamide 120 mg/kg
and total body irradiation, total dose of 1375 cGy.GVHD prophylaxis consisted of cyclosporine A, 3
mg/kg on day 21 and continued until the patient tol-
erated oral administration. Methotrexate was given i.v.
at a dose of 15 mg/m2 on day11 after transplantation,
and 10 mg/m2 on days 13, 6, and 11.
All patients were admitted to a dedicated Bone
Marrow Transplant Unit with laminar airflow or
high-efficiency particulate air filtered rooms under
conditions of reverse isolation. Acyclovir, fluconazole,
and fluoroquinolone were given to recipients in both
groups for prophylaxis against viral, fungal, and
gram-negative bacterial infections, respectively. The
National Cancer Institute Common Toxicity Criteria
version 2.0 was used for the evaluation of regimen-
related toxicity [34]. GVHD was graded by an estab-
lished GVHD severity scale [35-37].
The standard treatment for neutropenic fever and
infiltrates in the posttransplantation period at the Indi-
ana University Stem Cell Transplant program in-
cluded a thorough physical examination and chest
radiograph, sputum cultures, and empiric antibacterial
coverage, including vancomycin and cefepime or mer-
openem. Most patients underwent bronchoscopic ex-
amination for persistent fever and infiltrates at 5 days
and as clinically indicated, and the initial empiric anti-
fungal therapy was voriconazole. CMV prophylaxis
was administered with gancyclovir followed by weekly
surveillance and preemptive therapy [38,39].
The institutional review board at Indiana Univer-
sity approved the protocol for data collection and
a database was created using Excel (Microsoft Corpo-
ration, Redmond, WA). The medical records of the 2
groups were reviewed, including medical histories,
transplantation hospitalization summaries, out-patient
visit summaries, and radiological, pathological, and
pulmonary function studies. The following pulmonary
complications were documented: (1) pulmonary
edema; (2) infectious pneumonia; (3) noninfectious in-
flammatory pneumonitis; (4) BOS; (5) aspiration pneu-
monitis; (6) thromboembolic disease; (7) sinusitis; (8)
pleural effusion; and (9) cardiac-related pulmonary
edema [12,16,17,32,40-45]. Definitions of these com-
plications are described in Table 1. Pulmonary com-
plications were categorized by time of onset after
transplantation as follows: (1) the initial 6 months after
transplantation; and (2) 6 months or greater after
transplantation.Statistical Analysis
The chi-square test was used to test the differences
in percentages of the various pulmonary complications
between the 2 treatment arms in the entire cohort, and
in different subgroups of the population. When the
number of specific pulmonary complications was small,
the Fisher exact test was used. Means and medians of
continuous variables were calculated for each arm.
Table 1. Definitions of Pulmonary Complications (All Parameters Need to Be Met)
Complication Definition
Pulmonary edema (1) Presence of characteristic infiltrates or pleural effusions; (2) negative cultures; and (3) beneficial response
to dieresis.
Infectious pneumonia (1) Presence of focal or diffuse infiltrate(s) on chest radiograph; (2) positive blood, bronchoalveolar lavage, or
sputum cultures; (3) beneficial clinical response to antimicrobial therapy; and (4) bacterial, viral, or fungal
pneumonias were classified based on documented isolation of the corresponding organism(s). We have an
immunosuppressed protocol for BAL in our institution. The BAL is reviewed immediately by the
pathologist, and cultures are subsequently sent. Pneumocystis is diagnosed by immunofluorescence.
Aspergillus and histoplasma are either diagnosed by culture isolation, by elevated BAL aspergillus
galactomannan, or histoplasma antigen levels. Viruses are diagnosed by a BAL respiratory viral panel.
Noninfectious-inflammatory pneumonitis (1) Diffuse or focal infiltrates by chest radiography; (2) no identifiable causative infectious agent; and (3) no
response to antimicrobial therapy or dieresis [12,40-44].
BOS [58] (1) Absence of active infection; (2) decreased FEV1 (<75% predicted); (3) FEV1/FVC ratio <0.7; (4) elevated
residual volume >120% predicted or expiratory chest CT revealing air trapping or lung biopsy revealing
constrictive bronchiolitis; and (5) in the absence of a lung biopsy, 1 other manifestation of cGVHD should
be present.
Aspiration pneumonitis (1) Localized or diffuse infiltrates on chest radiographs; and (2) presence of definite historical evidence of
aspiration.
Thromboembolic disease CT scan evidence of pulmonary emboli or Doppler evidence of deep venous thrombosis.
Sinusitis CT scan evidence of sinus mucosal thickening with characteristic symptoms.
Pleural effusion [17] (1) Noninfectious exudative pleural fluid; and (2) no evidence of malignancy.
Cardiac-related pulmonary edema [45] Post-HCT reduction in left ventricular function of >20% associated with pulmonary edema.
BAL indicates bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome; CT, computed tomography; cGVHD, chronic graft-versus-host disease;
HCT, hematopoietic cell transplant.
Thromboembolic disease includes both documented deep venous thrombosis and pulmonary embolism.
Pleural effusion includes only the non-infectious exudative effusions as transudative effusions were mostly in the setting of pulmonary edema.
Cardiac pulmonary edema primarily refers to cases in which there was a significant reduction in left ventricular function in association with pulmonary
edema.
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tween means, and median tests were used to test differ-
ences between medians. The time to first pulmonary
complication was calculated using the Cox propor-
tional hazards regression. Only several pulmonary
complications were compared using time-to-event
analysis, because of the very small sample size for the
other pulmonary complications. Kaplan-Meier analysis
with the log-rank test was applied to compare the risk of
pulmonary complications during the first 2 years after
transplantation between the 2 arms. All analyses were
performed using SAS 9.1.3 (SAS Institute, Cary, NC).RESULTS
Study Population
Sixty-two patients who underwent minimally in-
tensive NMAT and 48 patients who underwent con-
ventional allotransplantation for a variety of
hematologic malignancies were included in the study.
Table 2 demonstrates that the groups were similar
with respect to smoking status, rates of pretransplanta-
tion CMV seropositivity, diffusing capacity, and his-
tory of previous pulmonary disease. The subjects
(NMAT group) were comprised of an older popula-
tion compared to the controls (median age, 54.5 years
versus 40.5 years; P\ .01). More subjects developed
cGVHD (58% versus 35%; P5 .02); more subjects re-
ceived cells from matched unrelated donors compared
to controls, but this difference did not reach statisticalsignificance (48% versus 31%; P 5 .07). Median fol-
low-up for the NMAT cohort was 452.5 days com-
pared with 340 days for the conventionally
conditioned group (P 5 .70). This trend was related
to the fact that conventionally conditioned patients
were lost to follow-up at earlier time points.
The indications for HCT in both groups are sum-
marized in Table 2. The most common indication for
transplantation in both groups was acute myeloid
leukemia (AML). Significantly more patients in the
conventional transplantation group had acute lympho-
cytic leukemia (12.50% versus 1.61%; P 5 .042) and
chronic myelogenous leukemia (CML; 16.67% versus
3.23%; P 5 .020). Myelodysplastic syndrome (MDS)
was a more common indication for transplantation in
the nonmyeloablative transplantation group (27.42%
versus 6.25%; P 5 .005).
Pulmonary Complications
Table 3 illustrates that there was no difference in
the overall incidence of pulmonary complications be-
tween the NMAT group and the controls (69% versus
73%; P5 .68). There was also no difference in the in-
cidence of infectious and noninfectious pulmonary
complications. The frequencies of various viral and
fungal pulmonary complications (including aspergil-
lus) in the 2 cohorts were similar, except for CMV.
Five patients had CMV in the NMAT cohort, com-
pared with 1 patient in the conventional cohort.
In the first 6 months posttransplantation, controls
experienced a higher incidence of pulmonary
Table 2. Characteristics of the Study Population
Characteristics
Conventional
Transplantation
n 5 48 (%)
Nonmyeloablative
Transplantation
n 5 62 (%) P Value*
Demographics
Male 23 (48) 40 (65) .120
Female 25 (52) 22 (35) .120
Age, mean, year 38.49 47.76 <.0001
Age, median, year 40.5 54.5 <.01
Smokers 17 (36.96) 23 (38.33) .8848
Smoking history unknown 2 (4) 2 (4)
Comorbidities
CMV Ab positive
(donor or recipient)
39 (81.25) 47 (78.33) .7084
CMV status unknown 0 (0) 2 (3.22)
DLCO <60% predicted 15 (32.61) 23 (43.4) .2710
DLCO unknown 2 (4.17) 9 (14.5)
Previous pulmonary disease 11 (22.92) 22 (35.48) .1537
Acute GVHD 27 (56.25) 37 (59.68) .7178
Chronic GVHD 17 (35.42) 36 (58.06) .0184
Type of transplantation
MRD 33 (68.75) 32 (51.61) .0698
MUD 15 (31.25) 30 (48.39) .0698
Median follow-up (days) 340 452.5 .7019
Diagnosis at time of
transplantation
AML 19 (39.58) 22 (35.48) .694
ALL 6 (12.50) 1 (1.61) .042
CML 8 (16.67) 2 (3.23) .020
Chronic lymphocytic
leukemia
2 (4.17) 5 (8.06) .466
MDS 3 (6.25) 17 (27.42) .005
Plasma cell dyscrasia 2 (4.17) 3 (4.84) 1.000
Lymphoma 8 (16.67) 12 (19.35) .806
CMV indicates cytomegalovirus; DLCO, diffusing capacity for carbon
monoxide; GVHD, graft-versus-host disease; MRD, matched related do-
nor; MUD, matched unrelated donor; AML, acute myelogenous leuke-
mia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous
leukemia; MDS, myelodysplastic syndrome.
*To test for the difference between the values in the 2 groups, the t test
was used for continuous variables and the Pearson chi-square test or the
Fisher exact test for categorical variables.
Figure 1. Comparison of the incidence of pulmonary complications
between the nonmyeloablative and conventional conditioning cohorts
using Kaplan-Meier analysis plot shows a separation between the 2
curves at all time points favoring a lower incidence of pulmonary
complications in the minimally intensive conditioning group. The separa-
tion is highest in the first 100 to 400 days posttransplantation. The
observed differences did not reach statistical significance (P 5 .24).
PSCT indicates peripheral stem cell transplant; NMAT, nonmyeloablative
(minimally intensive) conditioning. Log-rank test was used to compare
the differences.
1830 Biol Blood Marrow Transplant 18:1827-1834, 2012K. J. Diab et al.complications overall compared to patients who
underwent NMAT, but this difference did not reach
statistical significance (62.5% versus 46.8%; P 5 .10).
There was a trend toward a higher incidence of
pulmonary edema (18.7% versus 9.7%; P 5 .17)Table 3. Pulmonary Complications in the Study Populations
Pulmonary
Complications
Conventional
Transplantation (%)
Nonmyeloablative
Transplantation (%) P Value
Overall 35 (72.92) 43 (69.35) .6833
Infectious 18 (37.50) 25 (40.32) .7635
Viral 9 (18.75) 12 (19.35) .9362
Fungal 7 (14.58) 6 (9.68) .4293
Bacterial 7 (14.58) 11 (17.74) .6570
Noninfectious
pneumonitis
6 (12.5) 12 (19.35) .3352
BOS 3 (6.25) 7 (11.27) .3618
Thromboembolic disease 6 (12.5) 5 (8.06) .4419
Aspiration pneumonitis 3 (6.25) 6 (9.68)
Sinusitis 17 (35.42) 11(22.92)
Pleural effusion 2 (4.17) 0 (0)
Cardiac-related
pulmonary edema
2 (4.17) 2 (3.23)
BOS indicates bronchiolitis obliterans syndrome.and infectious pneumonias (27.1% versus 14.5%; P 5
.10) in controls. The incidence of pulmonary compli-
cations occurring after 6 months posttransplantation
was similar between the groups, with the exception
that a higher incidence of infectious pneumonias
was observed in the NMAT cohort, a finding that
did not reach statistical significance (38.1% versus
20.7%; P 5 .12).
In patients older than 48 years, there was a trend
toward a lower incidence of overall pulmonary compli-
cations in the NMAT cohort compared to patients
who underwent conventional transplantation (74.4%
versus 100%; P 5 .09). In patients less than 48 years
of age, 64.9% of patients in the conventional cohort
had pulmonary complications versus 57.9% of patients
in the nonmyeloablative transplant cohort (P 5 .61).Kaplan-Meier Analysis
Kaplan-Meier analysis demonstrated a consider-
able separation between the 2 curves at all time points
after transplantation, which favored a lower risk of pul-
monary complications in the NMAT cohort of pa-
tients. The highest points of separation occurred at
the 100- to 400-day time points after transplantation.
The difference in pulmonary complications did not,
however, reach statistical significance (P 5 .24; Fig-
ure 1). Further analysis showed that the probability
of developing pulmonary edema and noninfectious in-
flammatory pneumonitis was not statistically different
between the 2 cohorts (P 5 .2062 and .3768, respec-
tively). The probability of infectious pneumonias in
the first 6 months posttransplantation was higher in
the conventional than the nonmyeloablative transplan-
tation cohort (P 5 .0953).
Figure 2. Comparison of overall mortality and pulmonary-related
mortality between the conventional and nonmyeloablative hematopoi-
etic stem cell transplantation cohorts. (A) Kaplan-Meier analysis show-
ing no significant difference in overall mortality between the 2 groups
(P 5 .43). (B) Kaplan-Meier analysis showing no significant difference
in pulmonary-related mortality between the 2 cohorts (P 5 .45).
PSCT indicates peripheral stem cell transplant; NMAT, nonmyeloablative
(minimally intensive) conditioning. Log-rank test was used to compare
the differences.
Biol Blood Marrow Transplant 18:1827-1834, 2012 1831Pulmonary Complications after Nonmyeloablative TransplantationKaplan-Meier analysis also showed that there is no
statistical difference in overall mortality or pulmonary-
associated mortality between the 2 groups, although
there was a trend towards lower mortality in the control
group that did not reach statistical significance (P5 .45
for pulmonary-related deaths, and .43 for overall deaths)
(Figure 2).DISCUSSION
Allogeneic HCT using myeloablative combina-
tions of chemotherapy and/or chemoradiotherapy
has been the procedure of choice for a number of
high-risk hematologic malignancies in patients who
have an available donor. This procedure is associated
with relatively highmorbidity andmortality, especially
in older and debilitated patients. Infectious and nonin-
fectious pulmonary complications are the most com-
mon causes of peritransplantation mortality and
critical illness, and are diagnosed in up to 60% pre-
mortem; the incidence in autopsy studies is as high as
80% [7,46,47].Nonmyeloablative transplantation was introduced
as an alternative to myeloablative conditioning for
older patients and/or those with multiple comorbid-
ities. This transplantation method is initially charac-
terized by a state of mixed chimerism; full donor
hematopoietic chimerism occurs over a period of
time posttransplantation, during which recipients
may be at lower risk for graft-versus-host reactions.
Disease control is at least partially dependent on
a graft-versus-malignancy effect of donor cells
[21,22,24,33,48-51]. The NMAT method described
in this study is irradiation-free and relatively low che-
motherapeutic dosages are used [33]. Therefore, it is
associated with little if any clinical mucositis, a feature
that is indicative of minimal tissue injury. There is also
a decreased duration of pancytopenia [20,23]. For
these reasons, a lower incidence of pulmonary compli-
cations in this population of patients might be ex-
pected. Nusair et al. [32] reported 53 patients who
underwent nonmyeloablative conditioning before al-
logeneic transplantation and found a low incidence
(32%) of overall pulmonary complications, including
noninfectious pneumonias. Remarkably, BOS and dif-
fuse alveolar hemorrhage did not occur in any patients.
A number of other studies demonstrated relatively
high occurrences of CMV, as well as fungal and bacte-
rial infections at later time points (more than 100 days)
posttransplantation in NMAT compared to patients
who underwent conventional transplantation [52-54].
Several reasons could be considered in explaining these
findings. Although minimally intensive conditioning is
associated with less severe neutropenia at early time
points after transplantation, a relatively low number
of na€ıve CD41 and CD81 lymphocytes is observed
1 year after transplantation in these patients [55]. A
comparable incidence of cGVHD, a condition that is
immunosuppressive by its nature, occurs in equal fre-
quency after NMAT compared to conventional trans-
plantation. Given that the patient population that
undergoesNMAT is on average 10 years older, the im-
munosuppressive effects of cGVHD may be expected
to be especially problematic in older-aged individuals
in that the immunologic suppression associated with
cGVHD may be complicated further by the immuno-
logic senescence associated with aging. Deficient T
cell immunity and high rates of cGVHD at later time
points in the NMAT groups have been implicated as
factors associated with the higher incidence of infec-
tious pulmonary complications in other cohorts
[26,29,30,52,53,55,56].
In the current study, a high incidence of pulmo-
nary complications overall was observed in the
NMAT and conventionally conditioned allogeneic
transplantation recipients (69% and 73%, respec-
tively). We found no significant difference in the inci-
dence of infectious and/or noninfectious pulmonary
complications between the 2 groups. There seemed,
1832 Biol Blood Marrow Transplant 18:1827-1834, 2012K. J. Diab et al.however, to be a trend toward an increased incidence
of BOS after NMAT, which may be related to the
higher incidence of cGVHD (58% versus 35%) ob-
served in the NMAT cohort. Infectious pulmonary
complications tended to occur at later time periods
(ie, more than 6 months posttransplantation) after
NMAT, and at earlier time periods after conventional
transplantation. Pulmonary edema tended to occur
earlier (ie, less than 6 months posttransplantation) in
the patients who underwent conventional transplanta-
tion. Kaplan-Meier analyses also demonstrated a ten-
dency toward an increased incidence of pulmonary
complications at earlier time periods in patients who
underwent conventional transplantation.
It is recognized that the median follow-up for the
groups, ideally equivalent, was 452.5 days compared
with 340 days for controls (P 5 .70); this difference
was attributed to a greater loss to follow-up of controls.
Although not statistically significant, if the reason for
shorter follow-up were related to symptomatic pulmo-
nary consequences, managed by, for instance, local
physicians, this might have affected this outcome.
In the current cohort, NMAT seemed to protect
against pulmonary complications in older individuals,
as a trend towards a lower incidence of overall pulmo-
nary complications in patients older than 48 years was
observed in the NMAT cohort compared to the con-
trols (74% versus 100%; P 5 .09). Definitive conclu-
sions cannot be made as this finding did not reach
statistical significance. Higher dosages of chemother-
apy and/or chemoradiotherapy have been implicated
by others as etiologically important in explaining
higher occurrences of noninfectious and infectious
pulmonary complications in the early peritrans-
plantation period [2-4,7]. There was no difference in
pulmonary-related mortality or overall mortality be-
tween the 2 cohorts in this study. This may be related
to the higher incidence of BOS and cGVHD in the
NMAT group compared with the conventional trans-
plantation group.
The incidence of overall pulmonary complications
in our study was higher than that reported in the study
byNusair et al. [32] (69% versus 32%), despite the lon-
ger median follow-up period in the Nusair et al. [32]
study (28.5 months versus 15 months). We observed
a higher rate of infectious pulmonary complications
(40% versus 17%) that included bacterial, fungal,
and viral etiologies, particularly CMV. BOS occurred
in 11% of patients in our study compared to none.
Some of the differences may be related to the higher
incidence of cGVHD in the current study (58% versus
11%). This seems to be secondary to the lower inci-
dence of cGVHD observed in the Nusair et al. [32]
study, rather than a particularly high rate of cGVHD
in the present NMAT cohort [32,52,57]. Other factors
that may have contributed to the difference in pulmo-
nary complications include the older mean age of thepatients in the current NMAT cohort compared to
the Nusair et al. [32] cohort (48 years versus 39 years).
The difference in the indications for transplantation in
the present cohort compared to the Nusair et al. [32]
cohort may have affected the outcome. A higher per-
centage of patients in the current study had AML
andMDS, whereas a significant proportion of their pa-
tients underwent transplantation for lymphoma and
CML. The higher rate of BOS in the current study
may be due to different definitions of irreversible air-
flow obstruction on pulmonary function testing.
An obvious limitation to this study is the retrospec-
tive nature that describes the experience of a single
bone marrow transplant center. Nonetheless, this
study represents one of the largest cohorts of patients
assessed for pulmonary complications after NMAT,
and is the only study that directly compares the inci-
dence of multiple pulmonary complications after
NMAT and conventional transplantation.
In conclusion, the frequency of pulmonary com-
plications after hematopoietic stem cell transplant,
pulmonary-related mortality, and overall mortality
seem to be similar after nonmyeloablative minimally
intensive conditioning or conventional myeloablative
conditioning. A high rate of infectious pulmonary
complications and BOS may be observed in patients
withNMAT, especially at later time periods posttrans-
plantation. The high incidence of cGVHD in this pop-
ulation of patients may partially account for the higher
than expected rate of pulmonary complications. Well-
designed prospective multicenter cohort studies are
needed to confirm these findings.ACKNOWLEDGMENTS
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